Zymeworks (ZYME) Other Non-Current Liabilities (2021 - 2026)
Zymeworks (ZYME) reported Other Non-Current Liabilities of $278000.0 for Q1 2026, down 67.52% on a YoY basis from $856000.0 in Q1 2025, and little changed sequentially from $278000.0 in Q4 2025.
Zymeworks (ZYME) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Zymeworks (ZYME) has 6 years of Other Non-Current Liabilities data on file, last reported at $278000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities fell 67.52% year-over-year to $278000.0; the trailing twelve-month figure through Mar 2026 stood at $278000.0 (down 67.52% YoY), and the FY2025 full-year result was $278000.0, down 69.88% from the prior year.
- Other Non-Current Liabilities held at $278000.0 in Q1 2026, from $278000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $3.6 million in Q2 2023 to a low of $278000.0 in Q3 2025.
- A 5-year average of $1.4 million and a median of $929000.0 in 2024 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities tumbled 90.01% in 2023 and surged 217.06% in 2024, its largest moves.
- Tracing ZYME's Other Non-Current Liabilities over 5 years: stood at $1.6 million in 2022, then climbed by 3.59% to $1.7 million in 2023, then sank by 45.74% to $923000.0 in 2024, then slumped by 69.88% to $278000.0 in 2025, then changed by 0.0% to $278000.0 in 2026.
- Business Quant data shows ZYME's Other Non-Current Liabilities at $278000.0 in Q1 2026, $278000.0 in Q4 2025, and $278000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Zymeworks | 1.70 Bn | 1.34 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 278,000.00 |
| Dec 31, 2025 | 278,000.00 |
| Sep 30, 2025 | 278,000.00 |
| Jun 30, 2025 | 828,000.00 |
| Mar 31, 2025 | 856,000.00 |
| Dec 31, 2024 | 923,000.00 |
| Sep 30, 2024 | 929,000.00 |
| Jun 30, 2024 | 1.23 Mn |
| Mar 31, 2024 | 1.59 Mn |
| Dec 31, 2023 | 1.70 Mn |
| Sep 30, 2023 | 293,000.00 |
| Jun 30, 2023 | 3.60 Mn |
| Mar 31, 2023 | 3.60 Mn |
| Dec 31, 2022 | 1.64 Mn |
| Sep 30, 2022 | 2.93 Mn |
| Dec 31, 2021 | 2.75 Mn |